Welcome to our dedicated page for Rafael Holdings SEC filings (Ticker: RFL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rafael Holdings, Inc. (RFL) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, giving investors structured access to its official reports and transaction documents. Rafael Holdings’ filings describe it as a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage pharmaceutical and medical device companies, with a lead program focused on Trappsol® Cyclo™ for Niemann-Pick Disease Type C1.
Key filings include periodic reports and Form 8-K current reports that discuss quarterly and annual financial results, research and development spending, consolidation of subsidiaries such as Cyclo Therapeutics, Cornerstone and Day Three Labs, and capital structure changes. For example, Form 8-K filings detail the completion of a $25 million rights offering of Class B common stock, the issuance and listing of warrants in connection with the Cyclo merger, and subsequent information about those warrants, including their expiration and listing status.
Corporate governance and stockholder matters are documented in the company’s definitive proxy statement (DEF 14A) and related Form 8-Ks, which outline the election of directors, ratification of the independent registered public accounting firm, amendments to the 2021 Equity Incentive Plan and the company’s status as a controlled company under New York Stock Exchange rules. These filings also describe the dual-class share structure and voting rights associated with Class A and Class B common stock.
Investors can also review specialized filings such as Form 25, which in Rafael Holdings’ case relates to the removal from listing and registration of its warrants on NYSE American, and additional 8-Ks that report material events like board changes and executive appointments. On Stock Titan, AI-powered tools can help summarize lengthy documents such as proxy statements and earnings-related 8-Ks, highlight key terms around equity offerings, warrants and governance changes, and make it easier to understand how Rafael Holdings’ clinical focus and portfolio strategy are reflected in its SEC disclosure record.
Rafael Holdings (RFL)director effective 10/23/2025. The filing states the reporting person beneficially owns 0 shares of Class B Common Stock on a direct (D) basis and lists no derivative securities. The form is identified as filed by one reporting person.
Rafael Holdings (RFL) filed its annual report, highlighting a pivot to biotech led by Trappsol® Cyclo™ for NPC1. The company completed the Cyclo merger on March 25, 2025 and is running a global, double-blind Phase 3 trial that fully enrolled 94 patients; a June 2025 DMC review found the therapy well tolerated and recommended continuing to 96 weeks. An open-label sub‑study in patients under 3 years showed mostly stabilization or improvement on CGI‑S at 48 weeks, with manageable adverse events.
Beyond Trappsol® Cyclo™, Rafael owns majority stakes in LipoMedix, Cornerstone, Rafael Medical Devices, and Day Three. Rafael Medical Devices received FDA 510(k) clearance on December 11, 2024 for its VECTR System for minimally invasive ligament/fascia release. Cornerstone was restructured in March 2024, making Rafael a 67% owner. Day Three Labs sold certain assets and licensed Unlokt™ applications for a
As context, non‑affiliate market value was about
Rafael Holdings (RFL)Exhibit 99.1. The information is furnished under Item 2.02 and is not deemed filed. The materials also contain forward‑looking statements accompanied by cautionary language.
Rafael Holdings appointed Alan Grayson to its Board on October 23, 2025, and to the Compensation, Corporate Governance and Nominating committees. Director Markus Sieger was named to the audit committee and elected its Chairman. These appointments fill vacancies following the recent passing of Stephen Greenberg. A press release dated October 28, 2025, was filed as Exhibit 99.1.
Rafael Holdings (RFL) disclosed a Form 4 for its Chief Financial Officer. On 10/25/2025, 4,180 shares of Class B common stock were withheld for taxes upon the vesting of restricted stock, coded F, at a price of $1.35 per share.
Following this transaction, the CFO beneficially owns 260,641 shares directly. This total consists of 76,882 shares held directly, 82,509 fully vested restricted shares, and 101,250 unvested restricted shares.
The unvested restricted shares vest as follows: 6,250 quarterly from December 21, 2025 through December 21, 2026; 10,000 on each of October 25, 2026 and October 25, 2027; and 12,500 on each of January 13, 2026, January 13, 2027, January 13, 2028, and January 13, 2029.
Rafael Holdings, Inc. filed a current report to let investors know that a new slide presentation is available. The investor presentation, labeled Exhibit 99.1, is accessible on the company’s website at https://rafaelholdings.irpass.com/ starting October 10, 2025.
The material is furnished under Regulation FD, which is meant to provide fair disclosure of information. The company specifies that this information is not considered formally filed with the SEC or incorporated into other SEC documents. The presentation also includes forward-looking statements that are subject to the cautionary language contained within the slides.
Rafael Holdings, Inc. (RFL) Chief Financial Officer David Polinsky reported a non-open-market disposition of 1,284 Class B common shares on 09/23/2025 described as shares withheld by the issuer to satisfy tax obligations upon the vesting of restricted stock at an effective price of $1.48 per share. After this withholding, Mr. Polinsky beneficially owns 264,821 shares, consisting of 76,882 shares held directly, 76,689 fully vested restricted shares, and 111,250 unvested restricted shares with specified vesting dates through January 13, 2029. The Form 4 was signed by power of attorney on 09/25/2025.
Rafael Holdings, Inc. (RFL) Chief Financial Officer David Polinsky reported a transaction on 09/21/2025 in Class B common stock. The filing shows 1,970 shares were disposed at $1.49 per share, representing shares withheld by the issuer for tax purposes upon the vesting of restricted stock. After the reported transaction, Polinsky beneficially owns 266,105 shares, which include 76,882 shares held directly, 74,223 fully vested restricted shares, and 115,000 unvested restricted shares subject to a defined vesting schedule through January 13, 2029.
The disposition was reported on 09/22/2025 and appears to be a routine tax-withholding action tied to vesting rather than an open-market sale.
Rafael Holdings, Inc. director and 10% owner Jonas Howard S reported a non-derivative transaction on 09/13/2025. The filing shows 9,905 shares of Class B common stock were disposed at a price of $1.345 using transaction code F. After the reported transaction, the filing lists 267,707 shares beneficially owned by the reporting person directly.
The Form 4 also discloses a range of indirect holdings: multiple trusts and partnerships hold substantial Class B and Class A shares, including a total of 12,299,207 Class B shares reported for one trust and 787,163 Class A shares held indirectly by a partnership where the reporting person has sole voting and dispositive power. The filer signed via power of attorney on 09/16/2025.
Rafael Holdings insider activity: Joshua M. Fine, Chief Operating Officer, reported transactions on 09/03/2025. He disposed of 9,380 shares of Class B common stock, which are held jointly with his wife. On the same date he was granted 24,558 stock options with an exercise price of $1.38 that expire on 09/02/2035. The options vest in two equal installments of 12,279 shares on 09/03/2026 and 09/03/2027, conditioned on continuous service. Following these transactions he beneficially owns 24,558 option shares and reduced Class B share holdings by 9,380 shares.
FAQ
What is the current stock price of Rafael Holdings (RFL)?
What is the market cap of Rafael Holdings (RFL)?
